RANKL inhibitors for osteosarcoma treatment: hope and caution

Chen and collaborators propose RANKL blockade for the treatment and prevention of aggressive RANKL-overexpressing osteosarcoma (OS) in humans. Here we comment the main findings, putative applications and concerns. OS is the most common primary bone cancer, which occurs primarily in children and adol...

Descripción completa

Detalles Bibliográficos
Autores: Trinidad Alvarez, Eva Maria, González Suárez, Eva
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2016
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/125355
Acceso en línea:https://hdl.handle.net/2445/125355
Access Level:acceso abierto
Palabra clave:Osteosarcoma
Quimioteràpia
Chemotherapy
id ES_a79dbbcab7138fcb6ddcab1fa2f7c455
oai_identifier_str oai:diposit.ub.edu:2445/125355
network_acronym_str ES
network_name_str España
repository_id_str
spelling RANKL inhibitors for osteosarcoma treatment: hope and cautionTrinidad Alvarez, Eva MariaGonzález Suárez, EvaOsteosarcomaQuimioteràpiaChemotherapyChen and collaborators propose RANKL blockade for the treatment and prevention of aggressive RANKL-overexpressing osteosarcoma (OS) in humans. Here we comment the main findings, putative applications and concerns. OS is the most common primary bone cancer, which occurs primarily in children and adolescents, severely affecting survivors’ quality of life. Current treatment for newly diagnosed OS includes three main components: preoperative chemotherapy, surgical resection, and postoperative chemotherapy (1). This strategy has improved the outcome of patients with localized OS. However, patients with advanced, metastatic, and recurrent OSs continue to experience a quite poor prognosis. After aggressive treatment with both surgery and chemotherapy, the 5-year survival rate for OS patients with localized disease is about 65%, whereas it is less than 20% for patients with metastases. The use of adjuvant chemotherapy provides no survival advantage for patients with pulmonary metastases (2). So that, it is of particular importance to develop molecularly targeted therapy to treat patients with this metastatic bone malignancy, on the basis of in-depth understanding of signaling mechanisms involved in OS tumorigenesis.AME Publishing Company2016info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/125355Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.21037/atm.2016.12.10Annals of Translational Medicine, 2016, vol. 4, num. 24https://doi.org/10.21037/atm.2016.12.10info:eu-repo/grantAgreement/EC/H2020/682935(c) Annals of Translational Medicine, 2016info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1253552026-05-27T06:46:51Z
dc.title.none.fl_str_mv RANKL inhibitors for osteosarcoma treatment: hope and caution
title RANKL inhibitors for osteosarcoma treatment: hope and caution
spellingShingle RANKL inhibitors for osteosarcoma treatment: hope and caution
Trinidad Alvarez, Eva Maria
Osteosarcoma
Quimioteràpia
Chemotherapy
title_short RANKL inhibitors for osteosarcoma treatment: hope and caution
title_full RANKL inhibitors for osteosarcoma treatment: hope and caution
title_fullStr RANKL inhibitors for osteosarcoma treatment: hope and caution
title_full_unstemmed RANKL inhibitors for osteosarcoma treatment: hope and caution
title_sort RANKL inhibitors for osteosarcoma treatment: hope and caution
dc.creator.none.fl_str_mv Trinidad Alvarez, Eva Maria
González Suárez, Eva
author Trinidad Alvarez, Eva Maria
author_facet Trinidad Alvarez, Eva Maria
González Suárez, Eva
author_role author
author2 González Suárez, Eva
author2_role author
dc.subject.none.fl_str_mv Osteosarcoma
Quimioteràpia
Chemotherapy
topic Osteosarcoma
Quimioteràpia
Chemotherapy
description Chen and collaborators propose RANKL blockade for the treatment and prevention of aggressive RANKL-overexpressing osteosarcoma (OS) in humans. Here we comment the main findings, putative applications and concerns. OS is the most common primary bone cancer, which occurs primarily in children and adolescents, severely affecting survivors’ quality of life. Current treatment for newly diagnosed OS includes three main components: preoperative chemotherapy, surgical resection, and postoperative chemotherapy (1). This strategy has improved the outcome of patients with localized OS. However, patients with advanced, metastatic, and recurrent OSs continue to experience a quite poor prognosis. After aggressive treatment with both surgery and chemotherapy, the 5-year survival rate for OS patients with localized disease is about 65%, whereas it is less than 20% for patients with metastases. The use of adjuvant chemotherapy provides no survival advantage for patients with pulmonary metastases (2). So that, it is of particular importance to develop molecularly targeted therapy to treat patients with this metastatic bone malignancy, on the basis of in-depth understanding of signaling mechanisms involved in OS tumorigenesis.
publishDate 2016
dc.date.none.fl_str_mv 2016
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/125355
url https://hdl.handle.net/2445/125355
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.21037/atm.2016.12.10
Annals of Translational Medicine, 2016, vol. 4, num. 24
https://doi.org/10.21037/atm.2016.12.10
info:eu-repo/grantAgreement/EC/H2020/682935
dc.rights.none.fl_str_mv (c) Annals of Translational Medicine, 2016
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Annals of Translational Medicine, 2016
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv AME Publishing Company
publisher.none.fl_str_mv AME Publishing Company
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415793363517440
score 15.301629

Similares en LA Referencia